Señales en vivo de ARGX | Maximiza tus Ganancias con Getagraph.com

COMPRAR 2339 min ago

@ $386.33

Emitido: 3 may 2024 @ 15:42

Retorno: 0.48%

Señal anterior: may 3 - 13:57

Señal anterior: Vender

Retorno: -1.22 %

Live Chart Being Loaded With Signals

Commentary (3 may 2024 @ 16:00):
Our systems believe the stock currently is overvalued by 0.30% compare to its pairs and should correct downwards.

Stats
Volumen de hoy	139 374
Volumen promedio	270 366
Capitalización de mercado	23.07B
EPS	$0 ( 2024-05-02 )
Próxima fecha de ganancias	( $-0.710 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-75.38
ATR14	$12.72 (3.27%)

Correlación (AI algo v.1.1b): Overvalued: -0.30% $387.43 paired level. (El Algoritmo Rastrea Los Cambios De Las Acciones Más Correlacionadas En Tiempo Real Y Proporciona Una Actualización Instantánea)

Volumen Correlación

Largo: 0.69 (moderate)

Corto: 0.37 (neutral)

Signal:(52) Neutral

argenx SE Correlación

10 Correlaciones Más Positivas
MDLZ	0.898
VRTX	0.888
PLSE	0.885
NLTX	0.885
GRTX	0.881
CWST	0.878
ARCT	0.876
CRVL	0.872
CUE	0.872
HBIO	0.872

10 Correlaciones Más Negativas
FFBW	-0.915
HALL	-0.903
HTBI	-0.895
SATS	-0.893
LKFN	-0.888
IBEX	-0.886
OBT	-0.886
HSII	-0.882
VC	-0.88
SIDU	-0.878

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

argenx SE Correlación - Moneda/Commodity

0.59
( weak )

0.55
( weak )

0.47
( neutral )

0.22
( neutral )

-0.57
( weak negative )

argenx SE Finanzas

Annual	2023
Ingresos:	$1.23B
Beneficio Bruto:	$1.11B (90.39 %)
EPS:	$-5.16

FY	2023
Ingresos:	$1.23B
Beneficio Bruto:	$1.11B (90.39 %)
EPS:	$-5.16

FY	2022
Ingresos:	$410.75M
Beneficio Bruto:	$381.32M (92.83 %)
EPS:	$-13.05

FY	2021
Ingresos:	$497.28M
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-7.99

Financial Reports:

No articles found.

argenx SE

argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.

Actualizaciones en tiempo real para argenx SE [ARGX]

Upcoming Earnings Alert